MARKET

SONN

SONN

Sonnet BioTherapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3580
+0.0081
+2.31%
Opening 14:05 01/20 EST
OPEN
0.3500
PREV CLOSE
0.3499
HIGH
0.3644
LOW
0.3467
VOLUME
1.03M
TURNOVER
--
52 WEEK HIGH
3.415
52 WEEK LOW
0.3330
MARKET CAP
21.57M
P/E (TTM)
-0.3224
1D
5D
1M
3M
1Y
5Y
15 Stocks Moving in Monday's Pre-Market Session
Gainers IceCure Medical Ltd (NASDAQ: ICCM) rose 36.5% to $3.89 in pre-market trading. IceCure Medical, last week, received notice of intention to grant a European patent covering its cryogenic pump.
Benzinga · 12/27/2021 11:17
We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 12/20/2021 17:58
Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $2.5
Chardan Capital analyst Keay Nakae maintains Sonnet BioTherapeutics (NASDAQ:SONN) with a Buy and lowers the price target from $8 to $2.5.
Benzinga · 12/20/2021 13:34
25 Stocks Moving in Monday's Pre-Market Session
Gainers Society Pass Incorporated (NASDAQ: SOPA) rose 68% to $5.59 in pre-market trading after the company reported addition to the Russell 2000 Index.
Benzinga · 12/20/2021 11:35
The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · 12/17/2021 12:54
Sonnet BioTherapeutics EPS beats by $0.02
Sonnet BioTherapeutics (NASDAQ:SONN): FY GAAP EPS of -$1.02 beats by $0.02. Revenue of $0.48M Press Release As of September 30, 2021, Sonnet had $27.6M cash on hand. Jay Cross, CFO
Seekingalpha · 12/17/2021 11:37
Sonnet BioTherapeutics Files 10-K
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001106838/000149315221031781/form10-k.htm
Benzinga · 12/17/2021 11:32
Sonnet BioTherapeutics Provides Fiscal Year 2021 Business and Financial Update
PRINCETON, NJ / ACCESSWIRE / December 17, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the fisca...
ACCESSWIRE · 12/17/2021 11:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SONN. Analyze the recent business situations of Sonnet BioTherapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SONN stock price target is 3.167 with a high estimate of 5.00 and a low estimate of 2.000.
High5.00
Average3.167
Low2.000
Current 0.3580
EPS
Actual
Estimate
-0.27-0.20-0.14-0.07
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 26
Institutional Holdings: 3.01M
% Owned: 4.99%
Shares Outstanding: 60.25M
TypeInstitutionsShares
Increased
5
1.56M
New
5
179.61K
Decreased
1
844
Sold Out
2
1.00K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.44%
Pharmaceuticals & Medical Research
+0.59%
Key Executives
Chairman/President/Chief Executive Officer/Director
Pankaj Mohan
Chief Financial Officer/Treasurer/Secretary
John Cross
Chief Technology Officer
Susan Dexter
Chief Scientific Officer
John Cini
Other
Manuel Dafonseca
Other
Richard Kenney
Director
Donald Griffith
Independent Director
Nailesh Bhatt
Independent Director
Albert Dyrness
Independent Director
Raghu Rao
No Data
  • All
  • Financials
  • Insiders
More
About SONN
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company’s technology, namely fully human albumin binding (FHAB) helps to develop biologic medicines. FHAB utilizes a fully human single chain antibody fragment linked to either one or two therapeutic molecules capable of affecting single or bispecific mechanisms of action. The FHAB construct contains a domain, which is designed to bind to and hitch hike on human serum albumin for transport to targets, such as solid tumors or to the lymphatic system. It designed the construct to improve drug accumulation in specific tissues, as well as to extend the duration of activity in the body. FHAB development candidates are produced in a mammalian cell culture, which enables glycosylation, thereby reducing the risk of immunogenicity. FHAB technology can help in drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory and hematological conditions.

Webull offers kinds of Sonnet Biotherapeutics Holdings Inc stock information, including NASDAQ:SONN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SONN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SONN stock methods without spending real money on the virtual paper trading platform.